QuantHealth Secures Strategic Investment from Sanofi Ventures to Advance AI-Driven Clinical Trial Simulation
核心洞察
QuantHealth (搜索), an AI-driven clinical trial simulation company, secured strategic investment from Sanofi Ventures (搜索), bringing total funding to $30 million.
The company's platform generates millions of patient-level digital twins using real-world data to predict trial outcomes and optimize protocol design.
The investment supports an enterprise strategic relationship with Sanofi to integrate advanced AI technologies across R&D operations.
QuantHealth (搜索), a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures (搜索), the venture capital arm of global healthcare leader Sanofi. The investment brings QuantHealth's total funds raised to $30 million and will accelerate the company's efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development.
AI-Powered Digital Twins Transform Clinical Development
QuantHealth (搜索)'s platform enables pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By generating millions of patient-level digital twins, the platform predicts trial outcomes and optimizes protocol design, aiming to improve trial success rates, timelines, and cost efficiency.
The Tel Aviv-based company, founded in 2020, has access to over 350 million patient records and proprietary AI algorithms to simulate trials at scale. This approach allows pharmaceutical companies to optimize protocols, reduce risk, and accelerate development timelines before conducting actual clinical trials.
Strategic Partnership with Sanofi
The investment has catalyzed an enterprise strategic relationship that supports Sanofi's focus on integrating advanced AI and digital technologies to drive transformation across its R&D ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures (搜索), will join as an observer on QuantHealth (搜索)'s Board of Directors.
"We're proud to welcome Sanofi Ventures (搜索) as an investor and strategic ally in our journey," said Orr Inbar, CEO and Co-founder of QuantHealth (搜索). "Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development."
Industry Impact and Future Applications
"QuantHealth (搜索) has the potential to transform how clinical trials are designed and optimized," said Cris De Luca, Partner at Sanofi Ventures (搜索). "Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team."
Emmanuel Frenehard, Chief Digital Officer at Sanofi, emphasized the strategic importance of the partnership: "At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth (搜索) is central to our strategy. Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we're excited to explore this capability together."
Funding and Growth Strategy
QuantHealth (搜索) will use the funding to scale its AI-driven platform, enhance its digital twin simulation capabilities, and expand enterprise partnerships within the pharmaceutical industry. The company's technology addresses critical challenges in drug development by providing predictive modeling capabilities that can reduce the risk and cost associated with traditional clinical trials.
Sanofi Ventures (搜索) focuses on investing globally in early-stage biotech and digital health companies, with particular emphasis on immunology, oncology, rare diseases, vaccines, and digital innovation. This investment underscores a shared commitment to advancing drug development through the responsible use of artificial intelligence in life sciences.